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The fourth issue of volume two of Therapeutics and Clinical Risk Management
contains twelve review articles from international authors that address a broad range
of current and apposite topics within the remit of the journal.
Glaucoma is a multifactorial optic neuropathy that results in progressive vision
loss secondary to optic nerve atrophy and a reduction in retinal ganglion cells (RCGs).
Raised intraocular pressure (IOP) has been identified as a major risk factor in both
the development and progression of the condition. Hence, a primary aim of glaucoma
therapy is to effect a reduction in IOP to attenuate the risk of disease progression and
loss of vision; a strategy whose effectiveness has been demonstrated through recent
randomized, controlled clinical trials (RCTs). Brimonidine is the only selective alpha-
adrenergic receptor agonist currently approved for chronic use in glaucoma and has
established efficacy as mono-, adjunct, and replacement therapy in the treatment of
ocular hypertension and open-angle glaucoma. Louis Cantor opens this issue with a
consideration of the pharmacology, pharmacokinetics, and mechanism of action of
topical brimonidine. Cantor’s review continues with an assessment of clinical trials
of brimonidine in neuroprotection, the primary goal of which is the attenuation of
neuronal death and preservation of physiological function; a strategy that enables
treatment even in cases of unknown etiology. In addition, the author discusses the
different drug formulations available, brimonidine’s clinical efficacy in IOP reduction,
and addresses issues of safety and tolerability and patient acceptability and
compliance.
Asthma is a complex syndrome, characterized by a variable degree of airway
obstruction, with many clinical phenotypes in both adults and children. Despite
improvements in asthma treatment and increased understanding of the underlying
pathogenic mechanisms, the incidence and prevalence of asthma have been rising
worldwide. Asthma is now the most common disease in westernized countries.
Although the cause of the increase is unknown, it is clear that environmental triggers
play an important role. The majority of allergic asthmatic children are sensitive to
indoor allergens of which the house dust mite (HDM) appears to be the most important
environmental agent associated with asthma. There have been many attempts to lessen
the impact of asthma by reducing infestation with HDM. However, several meta-
analysis and review studies have suggested that simple interventions do little to reduce
HDM allergen levels. Vallance and colleagues have reviewed whether HDM
avoidance is efficacious in the treatment of asthma. In addition to a comprehensive
and critical review of the literature they also present findings of their own experience
with the association between HDM levels and asthma in Scotland, which has the
highest incidence of adolescent asthma in the world. Modern building regulations in
the UK have resulted in a warmer and more humid domestic environment, which is
the perfect microclimate for the proliferation of HDM. The authors point out that the
many studies designed to reduce the impact of asthma by reducing indoor allergens,
primarily HDM, have proved to be difficult and costly and their efficacy has been
unconvincing. They recommend an intervention strategy that uses the best evidence-
base from the most promising published methods, and to use this to impact on building
regulations to encourage change in the design, construction, and use patterns of
domestic buildings in the UK. Overall, the challenge appears to be to further refineTherapeutics and Clinical Risk Management 2006:2(1) 336
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the interventions to reduce HDM levels so that positive
clinical outcomes may be more easily demonstrated.
Over the past thirty years, an outstanding combination
of innovative clinical achievement coupled with
technological advancement and refinement has enabled the
fields of fertility medicine and research to experience
significant leaps forward in both basic knowledge and
translational activity. In that time, assisted reproductive
technologies (ART) have resulted in the birth of over 2
million children worldwide and in vitro fertilization (IVF)
techniques have developed to the level of a routine procedure
can be performed in 10 to 15 minutes in a physician’s
consulting room without the need for hospitalization or
general anesthesia. Wang and Sauer review the rapid and
exciting developments in the field since the pioneering birth
of Louise Brown in 1978 under the guidance of Patrick
Steptoe and Robert Edwards at Oldham General Hospital
and offer an intriguing insight into the evolution of modern
techniques for addressing the needs of infertile couples. The
authors present an overview of the initial work on IVF
during the 1970s that focused on women who presented
with tubal disease. They then move on to discuss the
advancements of the mid-1980s amongst women with
natural or premature ovarian failure and a discussion of the
increasing emphasis on women of advanced reproductive
age and the evolving role of embryo cryopreservation. The
developments of gamete intrafallopian transfer (GIFT) and
zygote intrafallopian transfer (ZIFT) are considered and
compared, together with the ooctye retrieval technique of
transvaginal ultrasound-guided transvaginal follicle
aspiration that rapidly became the procedure of choice
following its introduction in 1987. Until the late-1980s, male
infertility remained a rate-limiting factor in the overall
success rate of fertility treatment. The authors highlight the
role of a number of techniques that were developed to
address this situation, including partial zona dissection
(PZD) and subzonal insemination (SUZI). They then discuss
the later combined techniques of microepididymal sperm
aspiration and intracytoplasmic sperm injection (MESA-
ICSI) and include an assessment of the relative
developmental outcomes of children born via ICSI and
standard IVF procedures. An examination of the evolving
role of pre-implantation genetic diagnosis (PGD) includes
the transition from polymerase chain reaction (PCR)
techniques to fluorescence in-situ hybridization (FISH) and
a consideration of expanding the role of PGD to disorders
other than infertility, including HLA-typing for stem cell
donation and preservation of fertility amongst cancer
patients. The authors conclude with the observation that, in
spite of the significant technological advances of the past
three decades, continuing intense enquiry is required in order
to assess the long-term effects of a technique whose eldest
beneficiary is only 27 years old.
Rheumatoid arthritis (RA) is a prevalent condition whose
clinical sequelae can result in significant reductions in
functional capacity and quality of life with considerable
attendant debilitating impact upon psychological health.
Although there have been recent therapeutic advances, a
number of challenges remain: only a percentage of patients
will respond to the disease-modifying anti-rheumatic drugs
(DMARDs); toxicity and/or resistance dictate that another
sub-group requires combinations of DMARDs and the anti-
tumor necrosis factor-α (TNF-α) agents; and further sub-
groups gain no worthwhile benefit from any of the existing
therapies. There is a growing body of evidence to support
the role of T-cell activation in the development and
progression of RA. Abatacept is a soluble fusion protein
that comprises the extracellular domain of human CTLA4
and a fragment of the Fc portion of human immunoglobulin
G1 (IgG1) that targets T-cell activation. Edward Vital and
Paul Emery review abatacept’s mechanism of action and
studies examining its efficacy and safety. The authors present
an overview of the rationale for co-stimulation blockade in
RA, pharmacokinetic data from in vitro studies and a Phase
I dose-finding clinical trial, and immunological activity and
immunogenicity. A review of efficacy studies includes a
discussion of relevant outcome measures including the
American College of Rheumatology response rates, the
Disease Activity Score 28 (DAS28), and the Modified
Stanford Health Assessment Questionnaire (mHAQ). They
further discuss studies in patients who do not respond to
DMARDs, analyse findings relating to disease activity and
structural change, and functional capacity and quality of
life. In considering studies in patients who did not respond
to anti-TNF-α agents, the authors discuss the Phase III
ATTAIN trial including primary and secondary end-points
for disease activity and function and their correlations with
patients’ own perceived improvements. Considerable data
from Phase III trials indicate that abatacept is both safe and
effective and support its use in the management of RA, in
particular amongst patients who do not respond to DMARDs
and TNF-α agents. There is a brief discussion of abatacept’s
safety either as monotherapy or when administered in
combination with other RA therapies (the ASSURE trial)
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and the authors conclude with the opinion that abatacept
therapy in RA will represent the primary clinical application
of co-stimulation blockade with the potential to demonstrate
a role in the treatment of a broad range of immunological
disorders.
The myelodysplastic syndromes (MDS) constitute a
group of acquired disorders of the bone marrow caused by
defective clonal stem cells. Together with chronic
lymphocytic leukemia, they represent the most frequently
occurring hematological malignancy, with an incidence of
15 to 50 new cases/100 000/year. MDS are characterized
by advancing bone marrow failure, increased risk of life-
threatening infection, and myeloid cell abnormalities.
Although the natural history of MDS is variable,
approximately 30% of cases transform into acute
myeloblastic leukemia and there are high rates of morbidity
and mortality secondary most commonly to bleeding and
infection. MDS present as a variety of sub-types, the number
of which is dependent upon the classification system: the
French American British (FAB) system identifies five
morphological sub-groups with prognostic importance; the
World Health Organization system includes seven sub-
groups; and the International Prognostic Scoring System
identifies those patients at enhanced risk of transformation.
Allogenic stem cell transplantation represents the only
curative therapy but is only suitable in a minority of cases,
the remainder of patients being managed conservatively
through combinations of infection prophylaxis, blood and
platelet transfusions, and growth factors such as
erythropoietin and granulocyte-colony stimulating factor.
Emerging candidate therapies include the methyltransferase
inhibitors (MTI) such as azacytidine, a chemically
synthesized nucleoside analogue that has the potential to
reverse gene methylation and is currently the only drug in
this class with US Food and Drug Administration approval
for use in all subtypes of MDS. Raj and Mufti outline and
review the role of and clinical evidence for azacytidine in
MDS. They begin with an introduction to classification
procedure and the role of epigenetics in assessing disease
progression and risk. They then move onto a discussion of
the rationale for azacytidine in MDS, and its chemical
structure and pharmacokinetics. An analysis of the three
successive cancer and Leukemia Group B (CALGB) studies
includes discussion of the Phase III randomized controlled
trial that demonstrated azacytidine’s effectiveness relative
to the best model of supportive care. The authors also
summarize the clinical response, relapses and toxicity, the
drug’s mechanism of action in MDS, and duration of therapy.
They conclude with a brief discussion of other MTI’s in
MDS, the role of combination therapy, and future directions
in the management of this group of hematological
conditions.
Psoriatic arthritis (PsA) is a progressive, unpleasant and
potentially debilitating inflammatory arthritis characterized
by joint pain and swelling, fatigue and moderate-to-severe
skin lesions. The condition can result in severe joint erosion
and attendant significant reduction in functional capacity
and quality of life. It is frequently misdiagnosed and,
together with a lack of disease classification guidelines and
consensus-led diagnostic criteria, this hampers accurate
estimates of prevalence and incidence. Although the
etiological and pathophysiological factors that contribute
to development of PsA remain to be fully elucidated, the
condition seems to arise from a complex interaction between
genes, environment, and the immune system. In particular,
developing insights into the fundamental immunological
mechanisms of the disease highlighted the role of TNF-α
in mediating the pathogenesis of PsA and led to the
development of a number of anti-TNF-α drugs for PsA
therapy. Philip Mease reviews the role of infliximab, a
chimeric, human–mouse IgG1 monoclonal antibody, in the
treatment of PsA. He discusses its clinical presentation and
sub-types together with the etiology and pathophysiology
of the condition before moving onto current treatment
approaches. He outlines the traditional role of the non-
steroidal anti-inflammatory drugs (NSAIDS) and DMARDs
and notes that both classes of drugs are hampered by
inadequate control, failure to halt disease progression and
poor compliance rates due to side-effects and lack of
efficacy. His discussion of infliximab includes thorough
discussions of the IMPACT and IMPACT II trials and the
subsequent multi-centre, randomized, double-blind,
placebo-controlled Phase III studies, SPIRIT in the US and
EXPRESS in Europe. The author concludes with a
consideration of other TNF-α agents and the newer T-cell-
directed agents for PsA treatment.
Skin and soft tissue infections (SSTIs) are one of the
most frequent sites of bacterial infection and concomitantly,
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in the US, rate as one of the most common reasons for both
institution of antibiotic therapy and admission to hospital.
Complicated SSTIs (cSSTIs) are by definition more
inherently serious. They represent a significant clinical
challenge, not only as they frequently present with
associated bacteremia and sepsis but also because the
underlying pathologies that predispose to their development
– such as host immunosuppression, surgery, diabetes
mellitus, and peripheral vascular disease – may mean they
are less sensitive to standard antibiotic therapy and require
in-patient surgical intervention and parenterally
administered drug regimens. Management of cSSTIs is
further complicated by the range of bacterial pathogens and
constantly evolving resistance to available antibiotics.
Meropenem is a broad-spectrum antibiotic of the
carbapenem class that demonstrates excellent therapeutic
activity across a range of pathogens commonly associated
with cSSTIs. In the first of two reviews of the treatment of
cSSTIs, Douglas Fish presents a comprehensive review of
meropenem and its use in these conditions. He begins with
an overview of the clinical characteristics of cSSTIs, their
associated bacterial etiology and the considerations
underpinning appropriate therapeutic interventions. The
author provides a thorough review of meopenem including
a consideration of its antibacterial activity and
pharmacokinetics and pharmacodynamics before moving
onto a discussion of the clinical data in which he provides
an in-depth critique of the largest and most recent study. In
discussing its role in cSSTIs, he highlights its excellent
activity against the bacteria most commonly associated with
these conditions; proven clinical efficacy; low toxicity;
competitive wholesale pricing; and possible advantages
relative to other available therapeutic agents; and concludes
with a personal recommendation regarding an appropriate
dosing regimen.
In the second review of antibiotic therapy in the treatment
of SSTIs, David Guay addresses the role of moxifloxacin,
one of the newer members of the fluoroquinone class of
antimicrobials. He comprehensively reviews the in vitro
antimicrobial activity of moxifloxacin and underscores the
fact that it demonstrates significantly greater in vitro activity
against potential Gram-positive and Gram-negative aerobic
pathogens in SSSIs, relative to earlier quinolones such as
ciprofloxacin. From a pharmacokinetic perspective,
moxifloxacin demonstrates good penetration of muscle,
subcutaneous adipose tissue, and inflammatory blister fluid
and the author provides a table of comparative
pharmacokinetic parameters in healthy adult volunteers. The
results of clinical trials are presented in light of the
limitations intrinsic to their interpretation: the problems
inherent in designing trials of SSTIs that are both rigorous
and reproducible; the majority of studies were underpowered
to avoid Type II statistical errors; and the consequent lack
of generalization of results. In addition, the author addresses
issues of safety and potential drug–drug interactions. Of
these, the sole pharmacodynamic interaction with potential
clinical relevance is the additive electrophysiological effects
of moxifloxacin when combined with other drugs with the
ability to prolong the QTc interval. However, a lack of
rigorous epidemiological and multi-dose studies at present
precludes an assessment of the clinical relevance of this
potential effect.
Pancreatic cancer is a highly aggressive malignancy that
is, for the most part, chemo-refractory and has a five-year
survival rate of approximately 2%; most patients present
with unresectable disease and survive for less than one year
after diagnosis. Gemcitabine monotherapy was adopted
worldwide as a standard of care in the therapy of advanced
pancreatic cancer following a randomized controlled trial
in which it showed significantly enhanced clinical benefit
and a modest increase in median survival relative to 5-
fluorouracil. However, continuing poor prognosis coupled
with conflicting data from trials of combination therapy
clearly indicate the need to continue the search for new and
more effective therapeutic strategies. The last ten years have
seen a considerable accrual of knowledge in the molecular
pathogenesis of pancreatic cancer and the identification and
development of novel potential therapies has arisen from
our enhanced understanding of the tumor/stroma/host axis
and the interface with genetics and epigenetics. Anomalies
in signal transduction via the epidermal growth factor
receptor (EGFR) exert influence at several key stages of
tumor development including proliferation, susceptibility
to apoptosis, invasion, angiongensis, and metastasis.
Exploitation of this pathway is showing promise in the
treatment of advanced pancreatic cancer, primarily through
the use of monoclonal antibodies against the extracellular
domain and small molecule tyrosine kinase inhibitors (TKIs)
that compete at the ATP binding site of the tyrosine kinase
domain.
Erlotinib is a quinazoline-based small molecule TKI with
high selectivity against the EGFR. Naureen Starling and
colleagues introduce the role of EGFR signaling in
pancreatic cancer and give an overview of the pre-clinical
evaluation of erlotinib in which they discuss the elucidation
of the pharmacology and preliminary pharmacokinetics ofTherapeutics and Clinical Risk Management 2006:2(4) 479
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erlotinib through early phase studies. Combination therapy
offers considerable benefit in the management of cancer
through the modulation of resistance, synergistic effects of
combined drugs, and attendant potential for an enhanced
effectiveness. The authors review the clinical development
of erlotinib/gemcitabine combination therapy for the
management of pancreatic cancer. They discuss the results
of the National Canadian Institute of Cancer international,
multi-centre, randomised, placebo-controlled Phase III trial
and the conflicting data from the TRIBUTE and TALENT
studies, noting that the latter studies’ failure to select for
potential responders to EGFR TKIs attenuated erlotinib’s
therapeutic effect. Two ongoing studies, TARGET and
SWOG, are mentioned briefly together with potential
erlotinib-associated toxicity and the importance of careful
evidence-based patient selection. The authors conclude with
the observation that recent findings, although small,
represent important progress and, notwithstanding
pharmacoeconomic and quality of life considerations, form
the basis for future multi-targeted approaches to a disease
that is both aggressive and difficult to treat.
Pain is a frequent outcome of cancer and its treatment.
Its prevalence and severity are in part dependent upon the
disease stage and the site of primary tumor and metastases,
with prevalence rates estimated at 30% amongst those
patients who are being actively treated for metastatic spread
and 60% to 90% of patients with advanced disease.
However, in spite of the existence of incremental, validated,
consensus-based guidelines for analgesia, pain control in
cancer is frequently sub-optimally managed. This appears
to be a result of a number of factors including concerns
regarding tolerance, side effects, and out-of-date knowledge
amongst both health professionals and patients. Opiates
represent the preferred treatment strategy for palliation of
severe pain amongst cancer patients and their use is guided
by the World Health Organization three-step analgesia
ladder, a flexible framework developed to assist in the
appropriate application of analgesic drugs. Mandala and
colleagues address the question of how to optimize the use
of opiates in the palliation of cancer pain by focusing on
four separate aspects of therapy. Firstly, they consider how
best to implement the use of opioids and make two
suggestions: (1) the necessity of appropriate assessment by
an inter-disciplinary team who can deliver a holistic
approach to pain control; and (2) the introduction of
straightforward protocols or guidelines to further assist in
management of symptoms. Secondly, they consider
approaches to optimize the use of morphine, which in spite
of being the most widely used and cost-effective opioid, is
limited by poor systemic availability of the orally
administered drug that results in inter-individual variability
in the dose-response. The authors discuss thoroughly the
dose-titration approach to administration and give a brief
overview of the role of spinal morphine. Thirdly, they
address the major clinical challenge of management of side
effects (including gastrointestinal and central nervous
system) and suggest a four-step approach including dose
reduction, toxicity management, opioid rotation, and
alternative routes of administration. Lastly, they consider
the role of other potent opioids including methadone,
oxycodone, and transdermal fentanyl.
The increase in antibiotic resistant strains of
microorganisms worldwide continues to be a major concern
that highlights the necessity for the development of new
and more effective treatments. While the contribution of
multi-resistant Gram-positive pathogens continue to be a
major problem in the hospital setting, the growing tendency
towards progressive shortening of hospitalization has led
to community-acquired infections involving Gram-positive
cocci becoming more common. It is therefore of note that
Roberto Manfredi has provided a comprehensive review of
the role of multi-antibiotic resistant Gram-positive
pathogens in both the hospital and community setting. The
review considers current guidelines for the management of
these infections, particularly in compromised individuals.
Their effective management is hampered by the spectrum
of available antimicrobial compounds being significantly
impaired in selection and clinical efficacy by the spread of
methicillin-resistant and more recently glycopeptide-
resistant Gram-positive microbial strains. In this regard the
potential contribution of linezolid a novel oxazolidinone
derivative is described in terms of microbiological
properties, clinical indications and effectiveness together
with tolerability, safety issues and pharmacoeconomic
assessments. Other important issues are also discussed
including the usefulness of linezolid in pediatric populations,
the presence of Gram-negative pathogens necessitating the
use of combination therapy and the degree to which
linezolid-resistance pathogens may in time prove
problematic.
Restless leg syndrome (RLS), also known as Ekbom’s
syndrome, is a prevalent sensorimotor and sleep disorder
characterized by sensations of discomfort deep within the
legs that can only be relieved by repetitive leg movements.
The pathogenesis of RLS, is probably a function of the
interaction between a lack of systemic or brain iron andTherapeutics and Clinical Risk Management 2006:2(4) 480
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inadequate subcortical dopaminergic neurotransmission.
The condition has been clearly defined since the mid-1940s;
however, in spite of this it remains poorly recognized and is
notable for its frequent misdiagnosis and inadequate
treatment. Cotter and O’Keefe examine the factors that
contribute to the condition being so frequently overlooked
(and that can result in a delay of over a decade for an accurate
diagnosis); outline contemporary approaches to its
pathogenesis and treatment; and enumerate the benefits to
the patient of adequate diagnosis and management. In laying
the groundwork for our understanding of RLS, the authors
elaborate upon the current diagnostic criteria, including
essential criteria and supportive and associated clinical
features; address a number of myths and misconceptions
underlying the condition; and discuss why a diagnosis of
RLS should be considered important and managed
accordingly. They also present a succinct discussion of the
therapeutic regimens available for the management of both
primary and secondary RLS and conclude with a brief
summary of treatment options.